GLG Partners’s Array Biopharma Inc ARRY Stock Holding History

GLG Partners’s Portfolio ARRY Stock Details ARRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-69,651	Closed	-$470K	–	495
2016 Q3	$470K	Buy	+69,651	New	+$269K	0.01%	390

Other funds holding ARRY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

GLG Partners's ARRY Position: Q4 2016 in Review

GLG Partners sold out of Array Biopharma Inc (ARRY) in Q4 2016, closing a stake of 69,651 shares — an estimated $470K sold.

GLG Partners first reported a position in ARRY in Q3 2016 and held it in 1 quarter. The position peaked at $470K in Q3 2016. 167 funds tracked by Wall St. Rank hold ARRY as of Q4 2016.

GLG Partners reported no remaining Array Biopharma Inc position as of Q4 2016 after selling out during the quarter.
GLG Partners sold 69,651 Array Biopharma Inc shares in Q4 2016, an estimated $470K.
GLG Partners first reported a position in Array Biopharma Inc in Q3 2016 and held it in 1 quarter.
GLG Partners's Array Biopharma Inc position peaked at $470K in Q3 2016.
167 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q4 2016.

Based on GLG Partners's 13F filing for Q4 2016, filed 14 Feb 2017.